FALLYPRIDE
NHL
National Cancer Institute (NCI)Small moleculePhase 1/2Active
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
18 Active assets in the NHL cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Isatuximab Indapta Therapeutics, INC. | Phase 2 | B |
Veltuzumab Gilead Sciences | Phase 1/2 | B |
Milatuzumab Gilead Sciences | Phase 1/2 | B |
1H-3-BENZAZEPIN-7-OL, 5-(7-BENZOFURANYL)-8-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-, (5S)- National Cancer Institute (NCI) | Phase 1/2 | CCC |
Oxygen University of Rochester | Phase 2 | CCC |
View all 32 →
Same molecule, other indications
FALLYPRIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →